| Patent Number |
Title Of Patent |
Date Issued |
| RE36575 |
Pyridine and thiazolidinedione derivatives |
February 15, 2000 |
| A compound of the formula: ##STR1## (wherein R.sup.1 is hydrogen or a lower alkyl) can be produced advantageously by (1) reacting a compound of the formula: ##STR2## (wherein R.sup.1 has the meaning given above) with a halogenating agent or sulfonyl halide to give a compound |
| RE35886 |
Phosphonic acid derivatives and use thereof |
September 1, 1998 |
| A phosphonic acid derivative compound represented by formula [I ] or a pharmaceutically acceptable salt thereof: ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 each represent hydrocarbon groups which may be substituted, except cases in which (1) R.sub.2 is unsubstituted methyl, ( |
| RE34414 |
Physiologically active substance P-23924, its production and use |
October 19, 1993 |
| The compound of the formula: ##STR1## wherein R.sub.1 is hydrogen, methyl or hydroxymethyl, R.sub.2 is hydrogen or methoxy, R.sub.3 is hydroxy or methoxy, and R.sub.4 is hydrogen or a group ##STR2## is novel, and the compound is of use as inhibitors of animal tissue fibro |
| 7375074 |
Body weight gain inhibitor |
May 20, 2008 |
| The present invention intends to provide a body weight gain inhibitor and the like. The ligand of the present invention is useful as a superior body weight gain inhibitor and the like, or for a screening of the superior body weight gain inhibitor and the like. |
| 7309693 |
Preventives and remedies for pulmonary hypertension |
December 18, 2007 |
| The present invention provides a prophylactic and/or therapeutic agent for pulmonary hypertension, comprising an antagonistic mutein of MCP-1 or a salt thereof, a DNA molecule comprising a nucleotide sequence encoding the antagonistic mutein of MCP-1, or a neutralizing antibody against |
| 7262185 |
Benzazepine derivative, process for producing the same, and use |
August 28, 2007 |
| The present invention provides a novel benzazepine derivative represented by formula: ##STR00001## wherein, R.sup.1 is a 5- or 6-membered aromatic ring, R.sup.2 is lower alkyl group, etc., Y is an optionally substituted imino group, ring A and ring B are independently an optionally |
| 7144720 |
Protein and DNA thereof |
December 5, 2006 |
| The present invention relates to a novel protein belonging to an ADAM family, a partial peptide thereof or a salt thereof, a DNA encoding the protein, a recombinant vector comprising the DNA, a transformant, a method for producing the protein, a medicine comprising the protein or the |
| 7067268 |
Antibodies and utilization thereof |
June 27, 2006 |
| The anti-19P2 ligand monoclonal antibodies of the invention (in particular P2L-1Ca) have very high binding ability and can neutralize the arachidonic acid metabolite releasing activity of the 19P2 ligand. Therefore, they can be used, among others, as diagnostic, prophylactic and/or t |
| 7064106 |
Gene and use thereof |
June 20, 2006 |
| A protein and DNA encoding the same are useful as preventives/remedies for diseases such as hypoglycemia, etc. The protein of the present invention is also useful as a reagent for screening a compound that inhibits the binding of the protein of the present invention to IRAP (insulin |
| 7053053 |
Humanin-like peptide and use thereof |
May 30, 2006 |
| A novel polypeptide having a cell death inhibitory activity and use thereof is provided. The polypeptide and the polynucleotide encoding it can be used as a diagnostic, therapeutic or prophylactic agent for various diseases and disorders. Certain suitable diseases and disorders which |
| 7045497 |
Use of peptide |
May 16, 2006 |
| The present invention relates to use of peptide to which G-protein coupled receptor protein recognizes as a ligand. Since the ligand polypeptide of the present invention has a stimulating action on oxytocin secretion, it is useful as a drug for ameliorating, preserving or treating variou |
| 7008950 |
Benzofurans as suppressors of neurodegeneration |
March 7, 2006 |
| A compound of the formula: ##STR00001## wherein R.sup.1 and R.sup.2 each is H or a hydrocarbon group which may be substituted, or R.sup.1 and R.sup.2 form a 3- to 8-membered carbo or heterocyclic ring which may be substituted; R.sup.3 is H, a lower alkyl which may be substituted or an |
| 7001997 |
Proteins, their production and use |
February 21, 2006 |
| This invention relates to a novel metalloprotease having a proteolytic activity, its partial peptide or a salt either of them, a DNA coding for the protein, a recombinant vector comprising the DNA, a transformant carrying the recombinant vector, a process for producing the protein, a |
| 6991908 |
Antiobestic agents methods for screening antiobestic agents and kits comprising same |
January 31, 2006 |
| The present invention provides a method for screening a compound or its salt that alters the binding property between MCH or its salt and SLC-1 or its salt, characterized by using MCH or its derivative or a salt thereof and SLC-1 or its salt is useful for screening an SLC-1 agonist w |
| 6953789 |
Thiol compounds, their production and use |
October 11, 2005 |
| The present invention provides a compound represented by Formula: ##STR1##wherein ring A and ring B may be same or different and each is an optionally substituted homocyclic or heterocyclic ring and the like, each R.sup.1 may be same or different and is a hydrogen atom, an optionally |
| 6936602 |
Benzazepine derivatives, process for the preparation of the same and uses thereof |
August 30, 2005 |
| Compounds of the general formula (I): ##STR1##or salts thereof, which exhibit CCR5 antagonism and exert preventive and therapeutic effects against HIV infections: wherein R.sup.1 is a 5- to 6-membered aromatic ring which bears a substituent represented by the general formula: R-Z.sup |
| 6930185 |
Melanin-concentrating hormone antagonist |
August 16, 2005 |
| A melanin-concentrating hormone antagonist comprising a compound of the formula (I): ##STR1##wherein Ar.sup.1 is a cyclic group which may be substituted; X and Y are the same or different and are a spacer having a main chain of 1 to 6 atoms; Ar is a condensed polycyclic aromatic ring |
| 6930104 |
Heterocyclic derivatives |
August 16, 2005 |
| The object of the present invention is to provide soluble .beta.-amyloid precursor protein secretory stimulators, which are effective in treating neurodegenerative diseases as well as cerebrovascular disorder-induced neuronopathy. More specifically, the present invention provides a novel |
| 6924300 |
Oxyiminoalkanoic acid derivatives |
August 2, 2005 |
| To provide a novel oxyiminoalkanoic acid derivative which has excellent hypoglycemic and hypolipidemic actions and which is used for the prevention or treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance and impaired glucose tolerance.A compound represe |
| 6924292 |
Furoisoquinoline derivatives, process for producing the same and use thereof |
August 2, 2005 |
| A compound having a partial structure represented by Formula: ##STR1##or a salt thereof has an excellent phosphodiesterase (PDE) IV-inhibiting effect, and is useful as a prophylactic or therapeutic agent against inflammatory diseases, for example, bronchial asthma, chronic obstructive |
| 6911468 |
Tyrosine phosphatase inhibitors |
June 28, 2005 |
| A compound of the formula (I): ##STR1## wherein X.sub.1 and X.sub.2 are the same or different and each is a bond or a spacer having 1 to 20 atom(s) in the main chain; one of R.sub.1 and R.sub.2 is a cycle group having substituent(s) selected from 1) an optionally substituted carbox |
| 6911459 |
Pharmaceutical composition |
June 28, 2005 |
| Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabe |
| 6906177 |
GABA transporter protein and DNA thereof |
June 14, 2005 |
| The present invention provides a novel protein and its use. The protein or its salt, the partial protein, its amide or ester, or salts, and DNA encoding the same can be employed for obtaining antibodies and antisera, constructing the expression system of the protein of the present in |
| 6906055 |
Phosphonocephem compound |
June 14, 2005 |
| A cephem compound (particularly its crystal) represented by the formula [I], wherein X is CH.sub.3 COOH, CH.sub.3 CH.sub.2 COOH or CH.sub.3 CN, and n is 0 to 5, is useful as an antibacterial agent (particularly anti-MRSA agent) and shows superior quality such as high solid stability, |
| 6881842 |
Process for producing tricyclic fused heterocyclic derivative |
April 19, 2005 |
| A process for easily and industrially advantageously producing both a tricyclic fused heterocyclic derivative having acetylcholinesterase inhibitory activity and an intermediate for the derivative. The process for producing the target compounds comprises the following reaction. ##STR |
| 6881545 |
Polypeptides, their production and use |
April 19, 2005 |
| The present invention relates to the ligand polypeptide for the human pituitary- and mouse pancreas-derived G protein-coupled receptor proteins.The ligand polypeptide or the DNA which codes for the ligand polypeptide can be used for (1) development of medicines such as pituitary function |
| 6878831 |
Process for preparing optically active 2,3-dihydrobenzofuran compounds |
April 12, 2005 |
| A process for preparing optically active 2,3-dihydrobenzofuran compounds which comprises subjecting a 2,3-dihydrobenzofuran compound represented by the general formula or a salt thereof to optical resolution with an optically active acid compound: ##STR1##[wherein R.sup.1 and R.sup.2 |
| 6872718 |
Tricyclic dihydrobenzofuran derivatives, process for the preparation thereof and agents |
March 29, 2005 |
| A compound represented by the formula: ##STR1##wherein Ring A is a non-aromatic 5- to 7-membered nitrogen-containing heterocyclic ring which may be further substituted, Ring B is benzene ring which is further substituted, Ring C is a dihydrofuran-ring which may be further substituted |
| 6864367 |
Process for producing cyclic compound |
March 8, 2005 |
| A process suitable for safely mass-producing, through a short step, cyclic compounds useful in medicines, agricultural chemicals, foods, cosmetics, and chemical products or as intermediates therefor. The process, which is for producing a compound represented by the formula: ##STR1##{ |
| 6849738 |
Processes for the production of thienopyrimidine derivatives |
February 1, 2005 |
| The present invention provides a process for producing an intermediate for thienopyrimidine derivatives having the GnRH antagonistic activity at an industrial large scale.The process for production of the present invention relates to a process for producing a compound represented by the |
| 6844179 |
Protein and DNA thereof |
January 18, 2005 |
| The protein of the present invention and a DNA encoding the same can be used as therapeutic/prophylactic agents for diseases such as infectious diseases. The protein of the present invention is also useful as a reagent for screening a compound or its salt capable of promoting or inhibiti |
| 6838259 |
Process for producing kiss-1 peptide |
January 4, 2005 |
| A KiSS-1 peptide or a salt thereof can be produced in a large scale by subjecting a fusion protein or peptide in which a KiSS-1 peptide is ligated to the N-terminal of a protein or peptide having cysteine at the N-terminal, to the reaction of cleaving the peptide bond on the amino acid |
| 6833457 |
Process for preparation of benzylpiperidine compounds |
December 21, 2004 |
| According to the process as shown in the following scheme having a step for reacting Compound (I) with Compound (II) to produce Compound (III), benzylpiperidine compounds useful as synthesis starting materials of pharmaceutical agents, agricultural chemicals and the like can be produced |
| 6833381 |
TNF-.alpha. inhibitors |
December 21, 2004 |
| TNF-.alpha. inhibitors containing a heterocyclic compound having angiotensin II antagonistic activity which are useful as preventives/remedies for inflammatory diseases, etc. |
| 6827949 |
Wood preservative |
December 7, 2004 |
| A wood preservative that comprises as an active ingredient a Piper methysticum, plant or a processed product thereof or a compound represented by Formula (I): ##STR1##wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.16 are same or different and each denotes a hydrogen atom, hydro |
| 6825165 |
Betacellulin modification |
November 30, 2004 |
| The betacellulin mutein or its salt of the present invention is useful for better therapeutic drug for diabetes. Since they have intact BTC activity and reduced EGF activity, and no antigenicity-related problems. |
| 6815194 |
Cytidine deaminase |
November 9, 2004 |
| Genes encoding novel proteins named AID (Activation-Induced cytidine Deaminase), that are structurally related to APOBEC-1, an RNA editing enzyme, and have a cytidine deaminase activity similar to APOBEC-1, have been found by preparing cDNA libraries from mouse B cell clone CH12F3-2 |
| 6800778 |
Process for producing optically active naphthalene derivative and optical resolver therefor |
October 5, 2004 |
| The present invention provides a method of producing an optically active form of a compound represented by the formula (I) having a steroid C.sub.17,20 -lyase inhibitory activity and is useful as an agent for the prophylaxis or treatment of prostatism, tumor such as breast cancer, and |
| 6800611 |
Metastin derivatives and their use |
October 5, 2004 |
| The invention relates to metastin derivatives represented by the formula: X-AA.sub.1 -AA.sub.2 -AA.sub.3 -AA.sub.4 -Z (I), or a salt thereof, or a pro-drug thereof, which have cancer metastatis suppressing activity and cancer proliferation suppressing activity. The invention also relates |
| 6797483 |
Polypeptide and DNA thereof |
September 28, 2004 |
| The present invention relates to novel secretory polypeptides and precursor proteins thereof, which show a high homology to MIA (melanoma inhibitor activity)/CD-RAP (bovine cartilage-derived retinoic acid-sensitive protein); are specifically expressed in the cartilage tissue; and have an |
| 6794491 |
Polypeptides, their production and use |
September 21, 2004 |
| The present invention relates to the ligand polypeptide for the human pituitary- and mouse pancreas-derived G protein-coupled receptor proteins.The ligand polypeptide or the DNA which codes for the ligand polypeptide can be used for (1) development of medicines such as pituitary function |
| 6794383 |
Heart muscular cell apoptosis inhibitors and remedies/preventives for heart diseases |
September 21, 2004 |
| The present invention is intended to provide excellent preventives and/or remedies for heart diseases. Specifically, the present invention provides heart muscle cell apoptosis inhibitors, preventives and/or remedies for heart diseases, comprising a compound represented by the following |
| 6787650 |
Urea compounds, process for producing the same and use thereof |
September 7, 2004 |
| A compound of the formula: ##STR1## [wherein R.sup.1 is a hydrocarbon group which may be substituted; R.sup.2 is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; R.sup.3 is halogen atoms, a carbamoyl group which may be substituted |
| 6787082 |
Compressing mallet with coating treatment |
September 7, 2004 |
| The punch coated with Cr-Dope-N is advantageous as a punch for preparing tablets containing an acidic substance or an adhesive substance and is excellent in corrosion resistance and releasing property. |
| 6784314 |
Process for producing amine derivatives |
August 31, 2004 |
| This invention provides a convenient and industrially advantageous process producing amine derivatives having the action of inhibiting the secretion and accumulation of amyloid .beta. protein. ##STR1##In Compound (I), the ether linkage is selectively cleaved without cleaving the amid |
| 6777435 |
Crystals of an oxyiminoalkanoic acid derivative and their use as antidiabetics |
August 17, 2004 |
| Crystals of (E)-4-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyloxyimino]-4-phenylbuty ric acid (provided that crystals having a melting point of 126.degree. C. to 127.degree. C. are excluded), which have an excellent anti-diabetic action. |
| 6774221 |
Process for eliminating N-terminal methionine |
August 10, 2004 |
| A method for removing from a peptide the diketone of the methionine residue, and a method for manufacturing a peptide or salt thereof which does not possess an N-terminal methionine residue, characterized by having a peptide or salt thereof which possesses a diketone of the optionally |
| 6756472 |
Process for producing polymer |
June 29, 2004 |
| A process for producing a biodegradable polymer having free carboxyl at the .omega.-end charcterized by polymerizing a cyclic ester compound in the presence of a hydroxymonocarboxylic acid derivative having protected carboxyl or a hydroxydicarboxylic acid derivative having protected |
| 6756229 |
Human cell line showing stable expression of cytochromes P450 |
June 29, 2004 |
| This invention relates to cell lines that are obtained using cultured cell lines derived from human liver as a host and that stably express a number of human cytochromes P450. The human liver-derived cultured cell lines of the present invention are useful in, for example, analyzing an en |
| 6749864 |
Stabilized pharmaceutical composition |
June 15, 2004 |
| The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula ##STR1##wherein R.sup.1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl |
